Navigating Cigna Mavyret Prior Authorization for Hepatitis C Treatment

Successfully managing Cigna Mavyret prior authorization is critical for timely patient access to Hepatitis C treatment. Klivira provides a clear pathway to navigate Cigna Healthcare's requirements.

Mavyret (glecaprevir/pibrentasvir) is a high-volume prior authorization target for commercial and Medicare Advantage plans, including those administered by Cigna Healthcare. Revenue cycle directors and prior authorization coordinators face the challenge of understanding nuanced submission channels, policy requirements, and payer-specific processes to minimize delays and denials for this essential Hepatitis C medication.

Cigna Healthcare Submission Channels for Mavyret Prior Authorization

The appropriate submission channel for Mavyret prior authorization depends on whether the medication falls under the medical or pharmacy benefit. Cigna Healthcare directs medical-benefit prior authorization requests through CignaforHCP.com, its provider portal, which also supports X12 278 transactions via clearinghouses for impacted procedures.

Pharmacy Benefit Prior Authorization for Mavyret

For the pharmacy benefit, Express Scripts, operating under the Evernorth health services brand, manages prior authorizations for Cigna Healthcare members.
Retail pharmacy PA submissions for Mavyret route through Express Scripts' provider PA system.
Prescriber-initiated electronic prior authorization (ePA) workflows for Mavyret are supported through established partnerships with CoverMyMeds and Surescripts.
As a specialty medication, Mavyret may also be handled by Accredo, the specialty pharmacy under Express Scripts, which manages specialty-injectable and complex-medication PAs.

Utilization Management Policies and Criteria for Mavyret

Cigna Healthcare publishes comprehensive coverage policies and medical-necessity guidelines on its public provider site. These policies are versioned and dated, outlining clinical indications, conservative-care-trial requirements, and other criteria for medications like Mavyret. Providers should reference the specific policy number and effective date relevant to the patient's plan and state.

Electronic Prior Authorization (ePA) Posture for Cigna and Mavyret

Cigna Healthcare participates in the HL7 Da Vinci Project ecosystem, contributing to the advancement of electronic prior authorization standards. For pharmacy benefit medications like Mavyret, Express Scripts has long-established ePA capabilities through integrations with CoverMyMeds and Surescripts, facilitating streamlined electronic submissions for prescribers.

Common Denial Reasons and Appeal Pathways for Mavyret with Cigna

Denials for Mavyret prior authorizations from Cigna Healthcare are communicated via X12 277/835 transactions and status updates on CignaforHCP.com. Common denial categories include medical necessity due to insufficient documentation, lack of documented step therapy, non-formulary pharmacy issues (specific to the Express Scripts formulary), or benefit exclusion. Klivira's platform helps identify these patterns for proactive intervention.

Mavyret Appeal Process with Cigna Healthcare

Cigna Healthcare documents its appeal pathways on the provider portal and in the Cigna Provider Manual, with distinct processes for commercial and Medicare Advantage lines.
Peer-to-peer (P2P) reviews are available for clinical denials, offering an opportunity for direct discussion with a Cigna Healthcare medical director.
Expedited appeals can be requested for urgent care needs, following specific guidelines outlined by the payer.

Navigating Cigna Turnaround Times for Mavyret Prior Authorization

Prior authorization turnaround times for Mavyret with Cigna Healthcare are subject to state-mandated minimums for commercial plans and payer-published service-level targets. For Medicare Advantage plans, Cigna Healthcare is an impacted payer under CMS-0057-F, mandating 72-hour standard and 24-hour expedited PA timeframes on a phased compliance timeline. Proactive submission and comprehensive documentation are key to meeting these deadlines.

Frequently asked questions

Which Cigna entity handles Mavyret prior authorizations?

For pharmacy benefit Mavyret, Express Scripts (under the Evernorth brand) manages prior authorizations. If Mavyret is billed under the medical benefit (less common for this drug), Cigna Healthcare processes the prior authorization through CignaforHCP.com.

Can I submit Mavyret prior authorizations to Cigna electronically?

Yes, electronic prior authorization (ePA) for pharmacy benefit Mavyret is supported through Express Scripts' integrations with CoverMyMeds and Surescripts. For medical benefit PAs, Cigna Healthcare accepts X12 278 transactions via clearinghouses and direct submissions through CignaforHCP.com.

What are common reasons for Mavyret PA denials from Cigna Healthcare?

Common denial reasons include insufficient documentation of medical necessity, failure to meet step therapy requirements, issues with formulary compliance via Express Scripts, or site-of-service mismatches. Ensuring all clinical criteria are met and thoroughly documented is crucial.

How do I appeal a denied Mavyret prior authorization with Cigna?

Appeals for Mavyret denials can be initiated through CignaforHCP.com, following the specific pathways for commercial or Medicare Advantage plans. Peer-to-peer reviews are available for clinical denials, providing an opportunity to discuss the case with a Cigna Healthcare medical director.

Does Cigna Healthcare follow CMS-0057-F rules for Mavyret PAs?

Yes, Cigna Healthcare's Medicare Advantage plans are impacted payers under CMS-0057-F. This means they are subject to the mandated 72-hour standard and 24-hour expedited prior authorization turnaround times for Mavyret and other covered services.